102,670 research outputs found
Self-reported medication adherence and beliefs among elderly in multi-treatment: a cross-sectional study
No full textApplied Nursing Research
Available online 1 December 2015
In Press, Accepted Manuscript — Note to users
Cover image
Self-reported medication adherence and beliefs among elderly in multi-treatment: a cross-sectional study ☆ ☆☆ ★ ★★ ☆☆☆
Giancarlo Cicolini, MSN, PhDa, b, , Dania Comparcini, RN, MSN, PhDa, c, , Maria Elena Flacco, MDa, Lorenzo Capasso, MD, PhDa, Carlo Masucci, RN, MSNd, , Valentina Simonetti, RN, MSN, PhDa, c, ,
Show more
doi:10.1016/j.apnr.2015.11.011
Get rights and content
Abstract
Aim
To evaluate the association between adherence to treatment and beliefs about medications in multi-treated elderly patients.
Background
A large body of evidence documented the importance of adherence to therapy in predicting clinical outcomes, and the association between adherence and medication beliefs in patients of various ages and with different health conditions. However, so far only a few studies have specifically investigated the associations between medication beliefs and adherence among elderly in polypharmacy.
Methods
In this multicentre cross-sectional study we used the MMAS-8 and BMQ Scales to assess medication adherence and beliefs about medications, respectively.
Results
The final sample consisted of 567 patients. Patients reporting higher levels of necessity or concerns about their medicines showed higher adherence (OR: 1.61, and 2.02, respectively; both p<0.001). Accepting patients (high necessity and low concerns) were less likely (OR: 0.24; p<0.001) to report adherence than ambivalent ones (high necessity and concerns).
Conclusions
Medication adherence is related to high Necessity and Concern about treatment. In nursing practice it is important to understand the specific barriers to adherence and to engage patients in the implementation of strategies to improve adherence
Shimajiri-bay-2018
No full textRaw Dataset for Shimajiri Bay, research title:AFTER THE LONG SUMMER: DEATH AND SURVIVAL OF CORAL COMMUNITIES IN THE SHALLOW WATERS OF KUME ISLAND, FROM THE RYUKYU ARCHIPELAGO
Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors
No full textEBV-infected cells and EBV-associated tumors may evade CTL recognition by defective antigen processing, resulting in poor presentation of CTL epitopes. Since the proteasome is the major source of MHC class I-presented peptides, we analyzed the effect of proteasome inhibitors on the expression of surface HLA class I and the generation of EBV-derived CTL epitopes presented by the HLA-A2 and HLA-A11 alleles. Treatment with covalent and reversible inhibitors of the proteasome partially reduced the total and allele-specific expression of surface HLA class I in EBV-carrying LCLs. HLA-A2 expression was also decreased by treatment with leupeptin and bestatin, while HLA-A11 expression was affected by treatment with phenanthroline. Despite their general inhibitory effect on HLA class I expression, all proteasome inhibitors tested enhanced the presentation of 2 subdominant HLA-A2 epitopes from EBV LMP1 and LMP2, while the presentation of the immunodominant HLA-A11-restricted epitope from EBNA4 was inhibited by MG132 and lactacystin and increased by ZL3VS. Treatment with ZL3VS restored the presentation of endogenously expressed EBNA4 in I HLA-A11-positive BL cell line. These findings suggest that specific inhibitors of the proteasome may be used to increase the antigenicity of virus-infected and malignant cells that are per se inefficient at generating particular CTL target epitopes. © 2002 Wiley-Liss, Inc
Consorzio di probiotici / Probiotic mixture
No full textThis probiotic mixture is a high-potency probiotic supplement designed to "recolonize" the human gut. It wasn't just created in a lab. The scientists analyzed the microbiota of healthy people (those chosen as donors for fecal transplants) and tried to replicate that ideal "bacterial mix" in a capsule. It combines 9 different strains of beneficial bacteria with inulin, a fiber that acts as "food" for these microbes (this combination is called a synbiotic). To make sure the bacteria actually reach the gut without being destroyed by stomach acid, they are packed into special delayed-release capsules. It is mainly used when the intestinal ecosystem is out of balance: dysbiosis. This usually happens after taking antibiotics, during periods of high stress, or in Irritable Bowel Syndrome (IBS), bloating, and irregular digestion. It’s a gluten-free and lactose-free supplement
GM-CSF augments the IL-4-induced cytotoxic activity of human mononuclear cells in the presence of the mouse monoclonal antibody 17-1A
No full textBackground - The therapeutic effect of various modulators of the immune system might be increased if they are combined. Information on their activity using different schedules may be obtained from in vitro analyses. Methods - In this study, human peripheral blood mononuclear cells (lymphocytes and monocytes)(PBMC) were treated at the same time or sequentially with GM-CSF and IL-4 for different periods. Cytokine-activated PBMC were tested for cytolytic activity in a 18-h antibody-dependent cellular cytotoxicity (ADCC) assay using MAb 17-1A (mouse IgG2a) against SW1116 (a human colorectal carcinoma cell line). Results - The simultaneous incubation of effector cells with both cytokines did not increase the cytotoxicity induced by IL-4 or GM- CSF separately. Priming of PBMC with GM-CSF at the optimal concentration (10-3 μg/ml) for 1, 2 and 4h significantly enhanced the subsequent IL-4 induced activation of PBMC used at the optimal concentration (10-3 μg/ml). GM-CSF also augmented the cytotoxicity at a suboptimal concentration (10-4 μg/ml), but the lytic capability was less pronounced. Initial exposure of PBMC to IL-4 at optimal or suboptimal concentrations followed by stimulation with GM-CSF had no synergistic effect on ADCC. Conclusions - These results might have relevance as preliminary information to exploit the concept of combining different biological therapeutic agents for clinical protocols in cancer patients
Fecal microbiota transplantation: What’s new?
No full text: The gut microbiota is composed of trillions of different microorganisms: bacteria, archaea, phages and protozoa, which represent a real solid organ, with an approximate weight of 2 kg [...]
ARSA incidence and correlation with other strong markers of Down syndrome (DS) in 116 trisomy 21 fetuses assessed in a tertiary referral center.
No full text- …
